目的 探討纈沙坦膠囊聯(lián)合醋酸潑尼松片治療兒童原發(fā)性腎病綜合征的臨床療效。方法 選取2016年7月—2017年7月在周口市中心醫(yī)院接受治療的原發(fā)性腎病綜合征患兒120例為研究對(duì)象，采用隨機(jī)數(shù)表法將入選的患兒分為對(duì)照組和治療組，每組各60例。對(duì)照組口服醋酸潑尼松片，3片/次，3次/d，患兒的蛋白質(zhì)轉(zhuǎn)陰后，則更改為2片/次，1次/2 d。治療組在對(duì)照組的基礎(chǔ)上口服纈沙坦膠囊，患兒年齡<6.5歲：40 mg/次，患兒年齡≥6.5歲：80 mg/次，1次/d。兩組患兒連續(xù)治療8周。觀察兩組的臨床療效，比較兩組的腎功能指標(biāo)和血脂水平。結(jié)果 治療后，對(duì)照組和治療組的緩解率分別為75.0%、93.3%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血漿白蛋白（Alb）水平顯著升高，尿素氮（BUN）、24 h尿蛋白定量水平顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組腎功能指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組總膽固醇（TC）、尿肌酐（Cr）、三酰甘油（TG）水平均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組血脂水平明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 纈沙坦膠囊聯(lián)合醋酸潑尼松片治療兒童原發(fā)性腎病綜合征具有較好的臨床療效，能改善腎功能指標(biāo)，降低血脂水平，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Valsartan Capsules combined with Prednisone Acetate Tablets in treatment of primary nephrotic syndrome in children. Methods Children (120 cases) with primary nephrotic syndrome in Zhoukou Central Hospital from July 2016 to July 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Prednisone Acetate Tablets, 3 tablets/time, three times daily. After proteinuria negative, dose was changed to 2 tablets/time, 1 times every 2 days. Children in the treatment group were po administered with Valsartan Capsules on the basis of the control group, age < 6.5 years:40 mg/time, age ≥ 6.5 years:80 mg/time, once daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and renal function indexes and blood lipid levels in two groups were compared. Results After treatment, the remission rates in the control and treatment groups were 75.0% and 93.3%, respectively, and there was difference between two groups (P < 0.05). After treatment, Alb levels in two groups were significantly increased, but BUN and 24 h urine protein content levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And renal function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, TC, Cr and TG levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And blood lipid levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Valsartan combined with prednisone has clinical curative effect in treatment of primary nephrotic syndrome in children, can improve renal function indexes, and decrease blood lipid levels, with good safety, which has a certain clinical application value.